Bone Density Loss: Tenofovir has long been affiliated with a reduce in bone mineral density, escalating the risk of bone complications or fractures. HIV-one infected subjects on dolutegravir monotherapy demonstrated rapid and dose-dependent reduction of antiviral action with declines of HIV-one RNA copies per ml. The antiviral reaction was managed https://hivhub.in/product/viropil-tablet/